Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Rose 15.7% in First Quarter of 2022

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 46.1 million yuan in the first quarter of 2022, up 15.7% year-on-year.

Meanwhile, the company posted 2.3 billion yuan in revenue, up 7.7% year-on-year.

At the end of the reporting period, it had 6.7 billion yuan in total assets and 4.5 billion yuan in total liabilities, with a liability-to-asset ratio of 66.5%.